Beam – Base Editing SCD Data Update

Summary Beam Therapeutics announced updated biomarker data from the Phase 1/2 BEACON trial of ristoglogene autogetemcel (risto-cel), reinforcing its position as the leading base-edited cell therapy program in sickle cell disease ahead of a planned BLA submission by year-end 2026. What Happened Beam disclosed that…